Talent And Supply: Building A Foundation For The Future Of Biopharma

By Davy De Wilde, Jacob Slivka, Luke Heaven, and Mandar Dixit

The 21st century has been a transformative era for the pharmaceutical industry, with the COVID-19 pandemic acting as a powerful catalyst for innovation, investment, and an overall change in how we approach drug development. Specifically, the speed and scale of biopharma’s response to the outbreak demonstrated what we can achieve when there is a coordinated response to a unified mission. The result is a myriad of potentially longterm changes that could help bring new drugs to market faster. This comes at an especially important time, as we see a steady growth of revolutionary large molecule products aimed at addressing previously unmet medical needs. These modalities — which include RNA-based therapeutics, protein degraders, cyclopeptides, antibody drug conjugates, and gene therapies — are accelerating a biopharma revolution that stands to change the future of medicine.

However, in order to realize the promise of these novel therapies, we must adopt new strategies and business models that can help drive these discoveries from concept to reality. Continue reading to learn how to create future-ready facilities supported by advanced scientific knowledge and a secure supply chain that can handle the unprecedented demands and constraints of a post-COVID world.